anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a photoprotective agent for cosmetics and medicines, absorbing in a high absorbance in the UV-A-region, having a pointed band structure and soluble in an oil or water depending on substituents. SOLUTION: A compound expressed by formula I [R1 and R2 are each an electrophilic group such as cyano, an alkyl or the like; R3 is H, a 1-20C alkyl or the like; X is a divalent group or the like such as O or S; Z is a group or the like expressed by formula II (R4 is H, an alkyl or the like which may bonds to a benzylidene ring I or the like)], (e.g. a compound expressed by formula III) is used singly or together with a UV-absorbing compound for other known preparations for cosmetics and medicines as a photo-stable UV-filter in preparations for cosmetics and medicines for protecting the human skin and hair from the sun light. The compound expressed by formula I is included preferably in 0.1-10 wt.% based on the whole amount of the preparations for cosmetics and medicines.  The compound expressed by formula I is obtained by reacting, e.g. a compound expressed by formula IV with a compound expressed by formula V.
Diabetic retinopathy (DR) is a highly tissue-specific neurovascular complication of type 1 and type 2 diabetes mellitus and is among the leading causes of blindness worldwide. Pathophysiological changes in DR encompass neurodegeneration, inflammation, and oxidative stress. Current treatments for DR, including anti-vascular endothelial growth factor, steroids, laser photocoagulation, and vitrectomy have limitations and adverse reactions, necessitating the exploration of novel treatment strategies. This review aims to summarize the current pathophysiology, therapeutic approaches, and available drug-delivery methods for treating DR, and discuss their respective development potentials. Recent research indicates the efficacy of novel receptor inhibitors and agonists, such as aldose reductase inhibitors, angiotensin-converting enzyme inhibitors, peroxisome proliferator-activated receptor alpha agonists, and novel drugs in delaying DR. Furthermore, with continuous advancements in nanotechnology, a new form of drug delivery has been developed that can address certain limitations of clinical drug therapy, such as low solubility and poor penetration. This review serves as a theoretical foundation for future research on DR treatment. While highlighting promising therapeutic targets, it underscores the need for continuous exploration to enhance our understanding of DR pathogenesis. The limitations of current treatments and the potential for future advancements emphasize the importance of ongoing research in this field.
The application provides a compound acid stripping solution and a preparation method thereof, and relates to the technical field of chemistry. The complex acid stripping solution comprises a stripping component and a functional component. The stripping composition comprises: lactic acid, glycolic acid, mandelic acid, phytic acid. The functional components comprise: glycerol, pentanediol, hydroxyethyl cellulose, dimethyl glycyrrhizate, panthenol, allantoin, mussel mucin, arginine. The composite acid stripping liquid provided by the application comprises stripping components and functional components. The exfoliating elements consist of acids of different molecular weights. Each acid penetrates the skin at a different rate. The stripping process is enabled to be hierarchical and gradually penetrated, and the pain during and after operation is reduced. The added functional components can ensure the chemical stripping effect of stripping liquid, and simultaneously further reduce the stabbing pain in the operation and after the operation, improve the comfort level of the product in the use process, and are simple and easy to use and beneficial to popularization.
The invention belongs to the field of traditional Chinese medicine and relates to a medicine moxa stick for treating hysteromyoma. The moxa stick is in a cylindrical structure and comprises a filler and roll paper packaging the filler. The moxa stick is characterized in that the filler is prepared from 200-300 parts by weight of moxa wool, 10-15 parts by weight of medicinal evodia fruit, 10-15 parts by weight of rhubarb root and rhizome, 10-15 parts by weight of immature tangerine peel, 10-15 parts by weight of ground beetles, 10-15 parts by weight of Chinese angelica, 5-10 parts by weight of cowherb seeds, 15-20 parts by weight of bile arisaema, 15-20 parts by weight of stiff silkworm, 5-10 parts by weight of tofieldia divergens, 5-10 parts by weight of shrubberry rhodiola root, 4-5 parts by weight of chrysanthemum flower and 4-5 parts by weight of Chinese thorowax root. The moxa stick is prepared according to a theory of traditional Chinese medicine. The traditional Chinese medicines are combined to exert the maximum medicine effects for treating the hysteromyoma. The moxa stick is particularly suitable for treating phlegm-damp hysteromyoma and is less in toxic and side effects, low in cost and capable of treating both symptoms and root causes.
BACKGROUND/AIM: Difficult mask ventilation and difficult intubation are more common in obese patients. Ultrasound is a reliable and noninvasive method for evaluating the airway. The aim of this study was to investigate the contribution and availability of anterior neck soft tissue (ANS) thickness at different levels, tongue volume (TV), hyomental distance (HMD), the ratio of preepiglottic distance to distance between the epiglottis and the midpoint of vocal cords (PE/E-VC) measured by ultrasonography in predicting difficult airway in morbidly obese patients.
MATERIALS AND METHODS: Between March 2020 and November 2020, patients aged ≥18 years with a body mass index (BMI) of ≥40 kg/m2 who underwent elective surgery under general anesthesia were included in this prospective study at Fırat University Hospital. During the preoperative evaluation of patients, ultrasound was used to measure and record TV, ANS thickness at different levels, HMD, and ratio of PE/E-VC. Patients with difficult intubation were identified using the Cormack-Lehane classification system. Patients whohad difficulties with balloon mask ventilation were recorded. Subsequently, the parameters of patients with easy and difficult intubation were compared. In addition, the parameters of patients with easy and difficult mask ventilation were also compared.
RESULTS: The preepiglottic ANS thickness at the level of the thyrohyoid membrane and the PE/E-VC value in obese patients with difficult intubation were significantly greater than in obese patients with easy intubation (p < 0.001). In addition, TV (p < 0.001), preepiglottic ANS thickness at the thyrohyoid membrane level (p < 0.001), ANS thickness at the thyroid isthmus level (p = 0.002), ANS-suprasternal notch thickness (p = 0.004), and PE/E-VC (p = 0.005) values were significantly greater in obese patients with difficult mask ventilation.
CONCLUSION: Ultrasound may be a useful tool for predicting difficult airway and difficult mask ventilation. For this purpose, ANS thickness at different levels, PE/E-VC, and TV values measured by ultrasound can be used.
Patients will be given Panadol-extra (565 mg: 500 mg paracetamol and 65 mg caffeine) at specific time points to control pain and discomfort during orthodontic treatment. This group of patients will be followed up till the end of treatment.
In Part 1a, participants will receive a single oral dose of RO7049389 film coated tablet on Day 1 in dose-escalation cohorts with a starting dose of 150 milligrams (mg). The doses for subsequent cohorts will be defined by an adaptive approach based on the safety and PK data in previously-dosed healthy volunteers. In Part 1b, minimum 8 participants from Part 1a will be selected and 6 of whom will receive another single dose of RO7049389 on Day 16 after eating the standard US FDA-recommended high-fat and high-calorie breakfast.
It is intended to provide a tool, a procedure and so on which are useful in developing a therapeutic strategy efficacious in inhibiting or overcoming the resistance against a CD20-directed molecular-targeted drug. Thus, a CD20-negatively converted B cell malignant lymphocyte cell line is provided. Also, a model animal indicating the pathological conditions of CD20-negatively converted B cell malignant lymphocyte is provided. Further, a method of screening a substance, which is efficacious against CD20 positive B cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte, is provided. Furthermore, a drug against CD20 positive B cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte, which is characterized by being used together with a CD20-directed molecular-targeted drug, is provided. In one embodiment, a DNA methylase inhibitor or a histone deacetylase inhibitor is employed as the active ingredient.
FIELD: medicine. SUBSTANCE: method involves administering complex therapy combining local, physio- and drug therapy with antibiotic administration. Anti- Chlamydia activity antibiotic is injected into shin part of leg in lymphotropic mode. The drug is injected once a day from the first to the fifth day and each second day beginning from the seventh day. The total treatment course is 15 days long. The drug injection method allows one to achieve optimum in delivering and saturating lymphatic system with the antibiotic. To do it, the antibiotic is injected on the median line of the posterior surface of the shin part of leg at the boundary separating the upper and middle part at an angle of 45 deg. The antibiotic is diluted with water for injections to reach general volume of 7-8 ml. The injection rate is equal to 1 ml/min. Abactal or Riphogal preparation is administered as the antibiotic at a dose of 400 or 250 mg per one injection, respectively. EFFECT: enhanced effectiveness in arresting manifestations of Reiter syndrome symptoms. 3 cl, 1 tbl
If assigned to this condition, participants will be expected to complete twice-daily 17-minute tablet-assisted breathing exercises at home for four weeks. They will also receive brief phone check-ins with their study therapist weekly to review progress and troubleshoot any problems they may be experiencing. Last, these participants will have access to a paced-breathing app that provides audio recordings to maintain specified breathing rates for up to 10 minutes.
Patients will be recruited from the PI's population base at Highlands Sports Medicine Clinic. Patients in need of an ACL reconstruction will be asked if they are interested in participating in a study comparing BTB and QT autografts by the PI (Dr. Amit Momaya). The benefits and risks of each graft choice will be thoroughly explained. Both graft options are considered equally appropriate management. Interested patients will be screened for eligibility criteria by a research assistant; those matching eligibility will be consented and enrolled in person at the time of the visit.

Patients will be randomized per trial arm assignment to either (i) assignment "0" or (ii) assignment "1". To ensure randomization, a random number generator is used to assign patient numbers and study groups; these assignments are placed with consent information to remain blinded to research personnel and participants until the consent and enrollment process. We anticipate fifty participants per assignment and oen-hundred participants in total. Assignment 0 represents the BTB group. This procedure harvests the patient's middle third of the patella tendon through a single incision for the new ACL graft. When the graft is in place, the graft is secured using a surgical button at the femoral end and a non-absorbable screw at the tibial end. Assignment 1 represents the QT group. This procedure harvests the patient's quadricep tendon through a single incision then utilizes surgical buttons to fix the graft at the tibial and femoral ends. Following enrollment, patients will immediately be notified of their assignment. Patients will also complete KT-1000 manual maximum side-to-side difference measurements . The patient will then be scheduled for ACL reconstruction surgery according to their assignment.

Following reconstruction, standard of care rehabilitation and mobility instructions will be provided. Participants are expected to complete the usual standard of care 2 week, 6 week, 3 month, 6 month, and 9 month postoperative appointments. At the 2 week and 9 month postoperative visits, a routine x-ray will be performed. Aside from a singular KT-1000 measurement and repeated surveys, the patient should not expect any differences in their postoperative visits compared to if they had not participated in the study.
What is described herein is a stable and reduced-yellowing/non-yellowing synergistic preservative composition comprising: (i) about 0.1 wt. % to about 40 wt. % of dehydroacetic acid (DHA); and about 0.1 wt. % to about 99.9 wt. % of at least one aprotic solvent. Also described herein are aqueous and non-aqueous based preservative compositions for various end-user applications, and processes for preparing and using such compositions to reduce yellowing of DHA when added to the end-user applications.
Everolimus was not carcinogenic in mice or rats when administered daily by oral gavage for 2 years at doses up to 0.9 mg/kg, the highest dose tested. In these studies, AUCs in mice were higher (at least 20 times) than those in humans receiving 0.75 mg twice daily, and AUCs in rats were in the same range as those in humans receiving 0.75 mg twice daily.

Everolimus was not mutagenic in the bacterial reverse mutation, the mouse lymphoma thymidine kinase assay, or the chromosome aberration assay using V79 Chinese hamster cells, or in vivo following two daily doses of 500 mg/kg in the mouse micronucleus assay. 

In a 13-week male fertility oral gavage study in rats, testicular morphology was affected at 0.5 mg/kg and above, and sperm motility, sperm head count and plasma testosterone concentrations were diminished at 5 mg/kg which caused a decrease in male fertility. There was evidence of reversibility of these findings in animals examined after 13 weeks post-dosing. The 0.5 mg/kg dose in male rats resulted in AUCs in the range of clinical exposures, and the 5 mg/kg dose resulted in AUCs approximately 5 times the AUCs in humans receiving 0.75 mg twice daily. 

Oral doses of everolimus in female rats greater or equal to 0.1 mg/kg (approximately 0.13-fold the estimated AUC 0-24h in patients receiving the starting dose 0.75 mg twice daily) resulted in increased incidence of pre-implantation loss.
Choose both Neiguan point(PC6) and Zhongwan point(CV12). Manipulating until achieving a "de Qi" sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.
Patients enrolled in this observational prospective trial will be offered image-guided, volumetric modulated radiotherapy (IGRT-VMAT) in a single session (SDRT) of 21 Gy to the whole gland with a simultaneous boost of 24 Gy to the macroscopic PI-RADS driven (4-5) tumour(s). ADT will be prescribed concomitantly, as per standard of care. A real time non-ionizing prostate monitoring will be used to account for intra-fractional errors. If the dose constraints to the normal tissues are at risk, these will be prioritised over the aimed boost dose. The primary endpoint of the trial is the treatment related toxicity measured by the CTCAE v5.0. Secondary endpoints are quality of life in different domains (sexual, rectal , urinary) and biochemical outcome.

Patients will be followed at one month, then every 3 months for the first 12 months and every 6 months thereafter. Quality of Life will be prospectively evaluated through validated tools (ECOG, EPIC, IIEF-5, IPSS, ICIQ-SF) at various timepoints. Percentage or total mean score will be reported according the questionnaires, whether they grade values in a scale or use descriptive statistics. Kaplan-Meier curve analysis of biochemical relapse free survival (b-RFS) at 2 and 5-year bRFS for all patients will be estimated.
Angelica sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Patients starting cART. Grouping according to the time needed to reach viral loads below 1000, 500, 400, 200, 50 copies/ml, respectively.
This SH comparative study will evaluate safety and efficacy in a split face design using the CellFX System and pre-defined energy profile for all primary and secondary treatments based on Fitzpatrick Skin Types and tip size. The comparator group will be treated with the same standardized intralesional electrodesiccation procedure conducted by all participating clinical sites. Subjects with 4-10 qualifying SH lesions on the face except the scalp, nose and within the orbital region will be enrolled. Each subject will be evaluated by the blinded site investigator at 7-days, 30-days, and 60-days post-initial CellFX and Electrodessication treatments. At the 30-day follow-up visit, lesions will be evaluate using Global Aesthetic Improvement Scale (GAIS), for eligibility to receive an additional treatment. In case of a second treatment, the subject will be evaluated by the blinded site investigator at 30-days and 60-days post-retreatment. Photography of the study lesions will be captured along with the blinded site investigator assessments at all visits.
Coronary artery bypass surgery with use of the heart lung machine (on-pump surgery), is associated with the risk of peri-operative complications such as death, stroke, myocardial infarction, neurocognitive decline, and extended hospitalization. Bypass surgery on the beating heart without the use of the heart lung machine (off-pump surgery) has been reintroduced in clinical practice in order to reduce these complications. The Octopus cardiac wall stabilizer, developed at the UMC Utrecht, facilitates the safe construction of the grafts during the off-pump procedure. The expected advantages of off-pump surgery e.g. less-invasiveness, complete arterial revascularization, faster recovery and lower costs were the basis for the Octostent trial. We hypothesized that the off-pump surgical technique might offer an alternative for angioplasty with bare-metal stent-implantation.

The current study was designed as a randomized controlled multicenter trial comparing two strategies.
A nucleic acid vector comprising: (i) a promoter; (ii) a sequence encoding a HML-2 polypeptide operably linked to said promoter; and (iii) a selectable marker. Preferred vectors comprise: (I) a eukaryotic promoter; (ii) a sequence encoding a HML-2 polypeptide downstream of and operably linked to said promoter, (iii) a prokaryotic selectable marker; (iv) a prokaryotic origin of replication; and (v) a eukaryotic transcription terminator downstream of and operably linked to said sequence encoding a HML-2 polypeptide. Vectors of the invention are particularly useful for expression of HML-2 polypeptides either in vitro (e.g. for later purification). Or in vivo (e.g. for nucleic acid immunization). They are well suited to nucleic acid immunization against prostrate tumors. A preferred HML-2 is PCAV, which is located in chromosome 22 at 20.428 megabases (22q11.2).
The present invention relates to a method for preconditioning healthy donor's myoblasts in vitro before transplantation thereof in compatible patients suffering of recessive myopathies, particularly of muscular dystrophy. This in vitro preconditioning improves the success of the transplantation while not requiring an in vivo preconditioning of the patient's muscle by irradiation or by administering muscular toxin. The invention further relates to compositions comprising such preconditioned myoblasts. The preconditioning comprises pre-treating the transplanted myoblasts with human fibroblast growth factor (bFGF). The transplantation is made with the whole culture along with bFGF. A concentration of 100 ng/ml bFGF improved the myoblasts fusion by a four fold average.
Physicians will frequently encounter patients who report tinnitus. Tinnitus is a symptom whereby there is the perception of sound or sounds in the ear or head in the absence of an external source of sound. Most individuals experiencing tinnitus will have a neutral reaction to the percept, but in a small proportion of patients, tinnitus can be a debilitating symptom. When it causes burden, patients can be affected in multiple different facets of life, including impairment in sleep, hearing cognition and psychological and psychiatric well-being, often resulting in high healthcare utilisation and societal costs. Hence, chronic, disabling tinnitus is a complex condition with multifactorial causes and multiple perpetuating biopsychosocial factors. Despite efforts to increase knowledge about its pathophysiology and research into treatments, little impact on real-world clinical practice has been seen. There are no proven effective pharmacological treatments or complementary medicines specifically for chronic, disabling tinnitus. Despite this, there is a role for treating this condition through a multidisciplinary approach specifically targeting comorbid active psychiatric conditions, using hearing aids in appropriate clinical settings such as in those with a coassociated confirmed hearing loss, and specialised cognitive behavioural therapy for patients reporting bothersome tinnitus. Cognitive behavioural therapy remains the most valuable evidence-based intervention in this regard. This narrative review attempts to summarise the current understanding in terms of pathophysiology, assessment and treatment of tinnitus for the internal physician who may encounter patients with disabling, chronic tinnitus.